CN114163516B - 一种胶原蛋白源酪氨酸酶抑制肽及其制备方法与应用 - Google Patents
一种胶原蛋白源酪氨酸酶抑制肽及其制备方法与应用 Download PDFInfo
- Publication number
- CN114163516B CN114163516B CN202111480228.1A CN202111480228A CN114163516B CN 114163516 B CN114163516 B CN 114163516B CN 202111480228 A CN202111480228 A CN 202111480228A CN 114163516 B CN114163516 B CN 114163516B
- Authority
- CN
- China
- Prior art keywords
- tyrosinase
- peptide
- collagen
- tyrosinase inhibitory
- tilapia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 95
- 108060008724 Tyrosinase Proteins 0.000 title claims abstract description 76
- 102000003425 Tyrosinase Human genes 0.000 title claims abstract description 76
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 44
- 102000008186 Collagen Human genes 0.000 title claims abstract description 37
- 108010035532 Collagen Proteins 0.000 title claims abstract description 37
- 229920001436 collagen Polymers 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 230000002087 whitening effect Effects 0.000 claims abstract description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 239000006071 cream Substances 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 23
- 238000003032 molecular docking Methods 0.000 abstract description 21
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 abstract description 19
- 238000012216 screening Methods 0.000 abstract description 15
- 238000001042 affinity chromatography Methods 0.000 abstract description 14
- 241000251468 Actinopterygii Species 0.000 abstract description 11
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 abstract description 11
- 238000000034 method Methods 0.000 abstract description 6
- 239000002537 cosmetic Substances 0.000 abstract description 3
- 230000007062 hydrolysis Effects 0.000 abstract description 2
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 2
- 108091008146 restriction endonucleases Proteins 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 61
- 241000276707 Tilapia Species 0.000 description 57
- 239000000243 solution Substances 0.000 description 40
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 9
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 8
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000007853 buffer solution Substances 0.000 description 8
- 230000009920 chelation Effects 0.000 description 8
- 229910001431 copper ion Inorganic materials 0.000 description 8
- 235000019253 formic acid Nutrition 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000004365 Protease Substances 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 229910000365 copper sulfate Inorganic materials 0.000 description 6
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 238000004321 preservation Methods 0.000 description 6
- 108091005658 Basic proteases Proteins 0.000 description 5
- 230000010736 Chelating Activity Effects 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000002791 soaking Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 5
- 229910000368 zinc sulfate Inorganic materials 0.000 description 5
- 229960001763 zinc sulfate Drugs 0.000 description 5
- 241000276701 Oreochromis mossambicus Species 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 230000000415 inactivating effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 108090000526 Papain Proteins 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000010355 oscillation Effects 0.000 description 3
- 229940055729 papain Drugs 0.000 description 3
- 235000019834 papain Nutrition 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000021245 dietary protein Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- WHNCXIBKVUPNHR-UHFFFAOYSA-N 3,4-dihydroxy-1h-indole-2-carboxylic acid Chemical compound C1=CC(O)=C2C(O)=C(C(=O)O)NC2=C1 WHNCXIBKVUPNHR-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- HAVKMRGWNXMCDR-STQMWFEESA-N Arg-Gly-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HAVKMRGWNXMCDR-STQMWFEESA-N 0.000 description 1
- QCVXMEHGFUMKCO-YUMQZZPRSA-N Asp-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O QCVXMEHGFUMKCO-YUMQZZPRSA-N 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- PUUYVMYCMIWHFE-BQBZGAKWSA-N Gly-Ala-Arg Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PUUYVMYCMIWHFE-BQBZGAKWSA-N 0.000 description 1
- KAJAOGBVWCYGHZ-JTQLQIEISA-N Gly-Gly-Phe Chemical compound [NH3+]CC(=O)NCC(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 KAJAOGBVWCYGHZ-JTQLQIEISA-N 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- BPCLGWHVPVTTFM-QWRGUYRKSA-N Phe-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O BPCLGWHVPVTTFM-QWRGUYRKSA-N 0.000 description 1
- LGMBKOAPPTYKLC-JYJNAYRXSA-N Pro-Phe-Arg Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(O)=O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 LGMBKOAPPTYKLC-JYJNAYRXSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010039796 Seborrhoeic keratosis Diseases 0.000 description 1
- NJSPTZXVPZDRCU-UBHSHLNASA-N Ser-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)N NJSPTZXVPZDRCU-UBHSHLNASA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- UBDDORVPVLEECX-FJXKBIBVSA-N Thr-Gly-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(O)=O UBDDORVPVLEECX-FJXKBIBVSA-N 0.000 description 1
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 230000008101 melanin synthesis pathway Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 201000003385 seborrheic keratosis Diseases 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
- C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
- C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
- C12Y110/03—Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
- C12Y110/03001—Catechol oxidase (1.10.3.1), i.e. tyrosinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种胶原蛋白源酪氨酸酶抑制肽及其制备方法与应用，该制备方法包括以下步骤:(1)鱼皮胶原的提取；(2)限制性酶解；(3)固定化铜锌离子亲和层析；(4)液相色谱‑串联质谱联用鉴定；(5)分子对接筛选。筛选出4条与酪氨酸酶螯合最为紧密的肽，这4条肽的氨基酸序列分别为FSGLD、PFRMY、RGFTGM和APGAPGGGF。采用本发明方法制备的胶原蛋白源酪氨酸酶抑制肽具有良好的酪氨酸酶抑制活性，可作为美白功能成分用于化妆品中，具有良好的应用前景。
Description
技术领域
本发明属于动物源生物活性肽领域，具体涉及一种胶原蛋白源酪氨酸酶抑制肽及其制备方法与应用。
背景技术
黑色素是决定人类肤色的关键因子，正常含量的黑色素可在皮肤表皮形成保护屏障抵抗紫外线的损伤，但过量沉积会导致皮肤问题如痤疮、黄褐斑、黑素病、脂溢性角化病等。酪氨酸酶(tyrosinase,TYR)是黑色素生物合成的关键酶，催化从酪氨酸生成多巴醌的限速反应。针对黑色素过量沉积问题，抑制酪氨酸酶的活性是一种有效方式。尽管关于新型酪氨酸酶抑制剂的报道较多，但抑制效果不甚理想，只有少数几种如曲酸、对苯二酚、熊果苷等具有较好的抑制效果，但由于细胞毒性和诱变性被限制使用。因此，需要开发没有毒性和长期稳定性的新型抑制剂。
食物蛋白源酪氨酸酶抑制肽具有分子量小、易吸收、生物相容性好、安全性高的特点，在保健品及化妆品领域具有广阔的应用前景。食物蛋白源酪氨酸酶抑制肽的来源广泛，近年来以水产动物蛋白源为研究热点，但以罗非鱼皮为原料制备酪氨酸酶抑制肽未见报道。罗非鱼(Oreochromismossambicus)是一种淡水经济鱼类，我国产量居世界第一。罗非鱼的加工以冷冻鱼片为主，剩余部位作为副产物被加工成饲料或直接丢弃。但罗非鱼的加工副产物中含有约15％的粗蛋白，且鱼皮中含有丰富的胶原蛋白，是一种优质蛋白资源。因此以罗非鱼皮为原料制备酪氨酸酶抑制肽一方面可提高罗非鱼产业的精深加工水平与高值化利用率，另一方面可降低环境对加工废弃物的承受压力。
酪氨酸酶的活性中心是以两个铜离子为催化位点的疏水空腔，肽可与活性中心的铜离子形成相互作用力，螯合越紧密，使得铜离子催化活性越低，肽的抑制活性就越高。另外，TRP-2是酪氨酸酶相关蛋白家族的主要蛋白之一，在黑色素合成路径中负责将多巴色素催化生成二羟基吲哚-羧酸，此过程需要锌离子的参与。具有锌离子螯合活性的肽可与TRP-2竞争锌离子，阻断黑色素的生成。本发明通过固定化铜锌离子亲和层析提取具有酪氨酸酶抑制活性的肽组分，简化了纯化过程，提取得到的肽其酪氨酸酶抑制活性与传统手段获得的肽活性一致。
大量实验研究表明，含有天冬氨酸、苯丙氨酸、缬氨酸、赖氨酸、精氨酸、谷氨酸、丝氨酸等的肽表现出较强的金属螯合能力，尤其是天冬氨酸、苯丙氨酸、精氨酸及丝氨酸对铜与锌均具有很好的螯合能力，大量研究表明这几种氨基酸对肽的酪氨酸酶抑制活性具有突出贡献，能帮助肽更易螯合酪氨酸酶的活性中心。将铜锌离子用于固定化亲和层析，可纯化得到富含天冬氨酸、苯丙氨酸、精氨酸及丝氨酸等特征性氨基酸的肽组分。相较于化学合成酪氨酸酶抑制剂，活性肽具备更安全、更易吸收、效果更佳的优势。
《具有酪氨酸酶抑制作用的活性肽》借助在线酶切工具对胶原蛋白肽序列进行虚拟酶切，通过Discovery Studio软件对所得肽序列进行分子对接筛选，得到三条最具潜在酪氨酸酶抑制活性的肽Ser-Asp-Trp、Gly-Ala-Arg、Asp-Gly-Leu，其IC50值分别为0.84mg/mL、0.34mg/mL及0.15mg/mL。该专利通过虚拟酶解筛选酪氨酸酶抑制肽，无法保证实际酶解操作可获得相同肽段，亦无法得知纯肽组分的抑制活性是否高于混合肽组分，仅适用于作为纯肽成分添加的产品，提高了生产成本。
发明内容
为了解决现有技术存在的不足，本发明提供了一种胶原蛋白源酪氨酸酶抑制肽及其制备方法与应用。
本发明的目的通过以下技术方案来实现。
一种胶原蛋白源酪氨酸酶抑制肽，所述胶原蛋白源酪氨酸酶抑制肽的氨基酸序列为FSGLD、PFRMY、RGFTGM或APGAPGGGF。
所述胶原蛋白源酪氨酸酶抑制肽，其氨基酸序列分别为:FSGLD、PFRMY、RGFTGM和APGAPGGGF。五肽FSGLD、五肽PFRMY、六肽RGFTGM和九肽APGAPGGGF对酪氨酸酶活性的半抑制浓度(IC50)分别为0.279mg/mL、0.109mg/mL、0.377mg/mL和0.658mg/mL。
一种胶原蛋白源酪氨酸酶抑制肽的制备方法，包括以下步骤：
(1)鱼皮胶原的提取：取罗非鱼皮，加入NaOH溶液浸泡，浸泡后用流水洗至中性，再加入盐酸浸泡，用流水洗至中性后沥干打浆，将浆液置于恒温水浴，离心取上清液即得罗非鱼皮胶原提取液；
(2)限制性酶解：取罗非鱼皮胶原提取液，根据罗非鱼皮胶原提取液中的蛋白质质量加入蛋白酶，保温震荡反应，反应结束后沸水浴灭酶，抽滤后离心取上清液干燥，即得到罗非鱼皮酶解粉；
(3)固定化铜锌离子亲和层析：将罗非鱼皮酶解粉溶解在缓冲液中制成酶解液，通过固定化铜锌离子亲和层析柱，用洗脱液洗脱并收集纯化罗非鱼皮肽组分，冷冻干燥，得到纯化罗非鱼皮肽组分冻干样，即为具有铜锌离子螯合活性的罗非鱼皮肽；
(4)液相色谱-串联质谱联用鉴定：将纯化罗非鱼皮肽组分冻干样经由配备在线纳喷离子源的液相色谱-串联质谱联用(LC-MS/MS)分析，串联质谱图经过PEAKS Studioversion 10.6分析，所得罗非鱼皮肽序经De Novo检测及PEAKS搜库后选取Verifiable denovo sequences序列作为纯化罗非鱼皮肽最终组分；
(5)分子对接筛选：通过分子对接软件AutodockVina对所得罗非鱼皮肽序进行模拟对接，筛选出4条与酪氨酸酶螯合最为紧密的肽序列，并利用Pymol及Discovery Studio软件进行可视化处理。
进一步地，步骤(3)所述收集纯化罗非鱼皮肽组分的保留时间为38min。
进一步地，步骤(1)所述罗非鱼皮与NaOH溶液或盐酸的质量比为1:(5～10)；步骤(1)所述NaOH溶液的浓度为0.01～0.2mol/L，NaOH溶液浸泡的时间为20～30min；步骤(1)所述盐酸的浓度为0.01～0.2mol/L，盐酸浸泡的时间为10～30min；步骤(1)所述水浴的温度为50～65℃；步骤(1)所述水浴的时间为3～8h。
进一步地，步骤(2)所述蛋白酶为碱性蛋白酶、中性蛋白酶、胰蛋白酶、猪胰凝乳蛋白酶、木瓜蛋白酶中的任意一种；步骤(2)所述蛋白酶的添加量为蛋白质质量的0.5～2％。
进一步地，步骤(2)所述保温震荡反应的温度为25-55℃，所述保温震荡反应的时间为2～8h；步骤(2)所述灭酶的时间为15min；步骤(2)所述离心的转速为8000～10000r/min，离心的时间为15～30min。
进一步地，步骤(2)中蛋白酶的酶解时间优选为2～8h。
进一步地，步骤(3)所述固定化铜锌离子亲和层析柱用的硫酸铜溶液与硫酸锌溶液混合制备，其中硫酸铜溶液的浓度为0.2～0.6mol/L；步骤(3)所述硫酸锌与硫酸铜的物质的量之比为1:(1～3)。
进一步地，步骤(3)所述固定化铜锌离子亲和层析中，使用缓冲液的pH值为7.6，洗脱液是pH值为4.0且含NaCl浓度为0.5mol/L的溶液；步骤(3)所述固定化铜锌离子亲和层析中，样品上样量为5～10mg/次，螯合时间为40～90min，洗脱速度为1～5mL/min。
进一步地，步骤(4)所述液相色谱-串联质谱联用分析中，液相色谱仪上样体积为8～10μL，样品分离梯度为30～40min，柱流量为300～500nL/min，流动相的A相：体积百分比0.1％甲酸水溶液，流动相的B相：含体积百分比0.1％甲酸的乙腈(ACN)溶液，柱温为40℃，电喷雾电压2kV。
进一步地，步骤(4)所述液相色谱-串联质谱联用分析中，质谱仪(MS)参数设置如下：MS:质荷比(m/z)扫描范围＝100-1500；分辨率＝70000；离子捕获数量(AGC target)＝3e6；最大注入时间＝50ms；扫描电荷＝1-6；高能碰撞(HCD-MS/MS)(top 20)：分辨率＝17500；隔离窗口＝2质荷比；离子捕获数量＝1e5；最大注入时间＝45ms；碰撞能量＝28,动态排除时间＝30s。
本发明还提供了所述胶原蛋白源酪氨酸酶抑制肽在美白面霜中的应用。
本发明与现有技术相比，具有如下有益效果：
(1)以加工废料罗非鱼皮为原料，通过酶解与首次利用固定化铜锌离子亲和层析分离得到了能够有效抑制酪氨酸酶活性的五肽FSGLD、五肽PFRMY、六肽RGFTGM和九肽APGAPGGGF，在保证抑制效果同时减少纯化步骤，提高制备效率；使用两种金属离子筛选目标肽段，使获得的肽段具有更高的纯度。并明确了活性肽与酪氨酸酶螯合的作用机制，为酪氨酸酶抑制肽的制备提供了新途径，同时促进了低值水产品的高值化利用。
(2)本发明得到的4条活性肽通过螯合酪氨酸酶的活性中心抑制酶活性，从而减少黑色素的生成，因此可作为美白功能成分用于化妆品中，具有良好的应用前景。
(3)本发明使用两种金属离子筛选目标肽段，使获得的肽段具有更高的纯度。
附图说明
图1为五肽FSGLD与酪氨酸酶的分子对接图。
图2为五肽PFRMY与酪氨酸酶的分子对接图。
图3为六肽RGFTGM与酪氨酸酶的分子对接图。
图4为九肽APGAPGGGF与酪氨酸酶的分子对接图。
图5为固定化铜锌离子亲和层析色谱图。
具体实施方式
以下螯合具体实施例对本发明作进一步的说明。
实施例1
(1)取罗非鱼皮，加入0.01mol/L NaOH溶液，加入罗非鱼皮和NaOH溶液的质量比为1:5，浸泡20min后流水洗至中性；再加入0.01mol/L盐酸，加入罗非鱼皮和盐酸的质量比为1:5，浸泡10min后流水洗至中性，沥干打浆，将浆液置于50℃恒温水浴，3h后离心取上清液浓缩，得罗非鱼皮胶原提取液；
(2)取鱼皮胶原，加入碱性蛋白酶，碱性蛋白酶的添加量为罗非鱼皮胶原提取液中蛋白质质量的0.5％，在pH9.0，55℃条件下保温震荡反应2h，反应结束后沸水浴灭酶15min，抽滤，再以转速为8000r/min离心15min，取上清液干燥，得罗非鱼皮酶解粉；
(3)将罗非鱼皮酶解粉溶解在缓冲液中制成酶解液，以0.2mol/L硫酸铜溶液与0.2mol/L硫酸锌溶液等体积混合制备柱，将酶解液通过固定化铜锌离子亲和层析柱，上样量为5mg/次，螯合时间为40min，用pH值为7.6的缓冲液洗去未螯合组分，再用pH值为4.0且含NaCl浓度为0.5mol/L的溶液作为洗脱液洗脱螯合肽，洗脱速度为1mL/min，冷冻干燥，得到纯化罗非鱼皮肽组分冻干样，即为具有铜锌离子螯合活性的罗非鱼皮肽；
(4)将纯化罗非鱼皮肽组分冻干样经由配备在线纳喷离子源的液相色谱-串联质谱联用分析，液相色谱仪上样体积为8μL，样品分离梯度为30min，柱流量控制在300nL/min，流动相的A相：0.1％甲酸水溶液，B相：含0.1％甲酸的乙腈溶液，柱温为40℃，电喷雾电压2kV；质谱仪参数设置如下：MS:质荷比扫描范围＝100-1500；分辨率＝70000；离子捕获数量＝3e6；最大注入时间＝50ms；扫描电荷＝1-6；高能碰撞(top 20)：分辨率＝17500；隔离窗口＝2质荷比；离子捕获数量＝1e5；最大注入时间＝45ms；碰撞能量＝28,动态排除时间＝30s；
(5)分子对接筛选：通过分子对接软件AutodockVina对所得肽序进行模拟对接，筛选出4条与酪氨酸酶螯合最为紧密的肽，这4条肽的序列分别为FSGLD，PFRMY，RGFTGM和APGAPGGGF，并利用Pymol及Discovery Studio软件进行可视化处理。
图1为五肽FSGLD与酪氨酸酶的螯合图，图中五肽FSGLD与酪氨酸酶的CYS83及2个铜离子存在氢键作用力，说明五肽FSGLD进入酶活性中心与铜离子相互作用，从而抑制酶活性；图2为五肽PFRMY与酪氨酸酶的螯合图，图中五肽PFRMY与酪氨酸酶的HIS85、HIS244、ASN260、TYR65存在氢键作用力，说明五肽PFRMY与酪氨酸酶活性中心的组氨酸螯合紧密，既覆盖了催化位点，同时抑制了铜离子的催化活性；图3为六肽RGFTGM与酪氨酸酶的螯合图，图中六肽RGFTGM与酪氨酸酶的HIS85及SER282存在氢键作用力，说明六肽RGFTGM进入酶疏水空腔与铜离子附近的疏水性氨基酸螯合，占据酶与底物的作用位点；图4为九肽APGAPGGGF与酪氨酸酶的螯合图，图中九肽APGAPGGGF与酪氨酸酶的HIS244及ASN81存在氢键作用力，说明九肽APGAPGGGF进入酶疏水空腔与铜离子附近的疏水性氨基酸螯合，占据酶与底物的作用位点。
图5为固定化铜锌离子亲和层析色谱图。由图5可知，纯化罗非鱼皮肽组分的保留时间为38min。
相关测定方法介绍如下：
酪氨酸酶抑制率的测定方法：反应在96孔板中进行，反应体系为200μL。以磷酸缓冲盐溶液(PBS缓冲液)配制1mg/mL的L-多巴溶液，PBS缓冲液的pH值为6.8，浓度为0.2M。加入80μL的L-多巴溶液，再加入同等体积的酶解物(浓度为20mg/mL)，预培养5min后测定475nm处吸光值。最后加入40μL酪氨酸酶溶液(500U/mL)，37℃孵育15min再次测定475nm的吸光值。对照组以PBS缓冲液替代酶解物。酪氨酸酶抑制率按以下公式进行计算：
酪氨酸酶抑制率(％)＝(1-(A2′-A2)/(A1′-A1))×100，式中：A1，A2分别为不加酶解物组与加酶解物组预培养5min的吸光值；A1′，A2′分别为两组培养15min后的吸光值。
表1鱼皮胶原、碱性蛋白酶酶解物、纯化罗非鱼皮肽组分及纯肽的酪氨酸酶抑制率
由表1可知，罗非鱼皮胶原的酪氨酸酶抑制活性较低，其半抑制率IC50为50.13mg/mL；经过碱性蛋白酶酶解后其抑制活性显著提高，半抑制率IC50为19.87mg/mL；进一步通过固定化铜锌离子亲和层析纯化后其酪氨酸酶抑制率较鱼皮胶原提高了5倍。对液相色谱-串联质谱联用技术鉴定的肽序列进行分子对接筛选得到4条具有最高预测活性的肽，其酪氨酸酶抑制率较纯化罗非鱼皮肽组分提高了12倍以上，4条肽的酪氨酸酶抑制活性排序为PFRMY＞FSGLD＞RGFTGM＞APGAPGGGF。
实施例2
(1)取罗非鱼皮，加入0.2mol/L NaOH溶液，加入罗非鱼皮和NaOH溶液的质量比为1:10，浸泡30min后流水洗至中性；再加入0.2mol/L盐酸，加入罗非鱼皮和盐酸的质量比为1:10，浸泡30min后流水洗至中性，沥干打浆，将浆液置于65℃恒温水浴，8h后离心取上清液浓缩，得罗非鱼皮胶原提取液；
(2)取鱼皮胶原，加入胰蛋白酶，胰蛋白酶的添加量为罗非鱼皮胶原提取液中蛋白质质量的2％，在pH8.0，37℃条件下保温震荡反应4h，反应结束后沸水浴灭酶15min，抽滤，再以转速为10000r/min离心30min，取上清液干燥，得罗非鱼皮酶解粉；
(3)将罗非鱼皮酶解粉溶解在缓冲液中制成酶解液，以0.6mol/L硫酸铜溶液与0.2mol/L硫酸锌溶液等体积混合制备柱，将酶解液通过固定化铜锌离子亲和层析柱，上样量为10mg/次，螯合时间为90min，用pH值为7.6的缓冲液洗去未螯合组分，再用pH值为4.0且含NaCl浓度为0.5mol/L的溶液作为洗脱液洗脱螯合肽，洗脱速度为5mL/min，冷冻干燥，得到纯化罗非鱼皮肽组分冻干样，即为具有铜锌离子螯合活性的罗非鱼皮肽；
(4)将纯化罗非鱼皮肽组分冻干样经由配备在线纳喷离子源的液相色谱-串联质谱联用分析，液相色谱仪上样体积为10μL，样品分离梯度为40min，柱流量控制在500nL/min，流动相A相：0.1％甲酸水溶液，B相：含0.1％甲酸的乙腈溶液，柱温为40℃，电喷雾电压2kV；质谱仪参数设置如下：MS:质荷比扫描范围＝100-1500；分辨率＝70000；离子捕获数量＝3e6；最大注入时间＝50ms；扫描电荷＝1-6；高能碰撞(top20)：分辨率＝17500；隔离窗口＝2质荷比；离子捕获数量＝1e5；最大注入时间＝45ms；碰撞能量＝28,动态排除时间＝30s；
(5)分子对接筛选：通过分子对接软件AutodockVina对所得肽序进行模拟对接，筛选出4条与酪氨酸酶螯合最为紧密的肽，这4条肽的序列分别为FSGLD，PFRMY，RGFTGM和APGAPGGGF，并利用Pymol及Discovery Studio软件进行可视化处理。
实施例3
(1)取罗非鱼皮，加入0.1mol/L NaOH溶液，加入罗非鱼皮和NaOH溶液的质量比为1:8，浸泡25min后流水洗至中性；再加入0.1mol/L盐酸，加入罗非鱼皮和盐酸的质量比为1:8，浸泡20min后流水洗至中性，沥干打浆，将浆液置于60℃恒温水浴，5h后离心取上清液浓缩，得罗非鱼皮胶原提取液；
(2)取鱼皮胶原，加入木瓜蛋白酶，木瓜蛋白酶的添加量为罗非鱼皮胶原提取液中蛋白质质量的1％，在pH6.5，25℃条件下保温震荡反应8h，反应结束后沸水浴灭酶15min，抽滤，再以转速为9000r/min离心20min，取上清液干燥，得罗非鱼皮酶解粉；
(3)将罗非鱼皮酶解粉溶解在缓冲液中制成酶解液，以0.4mol/L硫酸铜溶液与0.2mol/L硫酸锌溶液等体积混合制备柱，将酶解液通过固定化铜锌离子亲和层析柱，上样量为8mg/次，螯合时间为60min，用pH值为7.6的缓冲液洗去未螯合组分，再用pH值为4.0且含NaCl浓度为0.5mol/L的溶液作为洗脱液洗脱螯合肽，洗脱速度为3mL/min，冷冻干燥，得到纯化罗非鱼皮肽组分冻干样，即为具有铜锌离子螯合活性的罗非鱼皮肽；
(4)将纯化罗非鱼皮肽组分冻干样经由配备在线纳喷离子源的液相色谱-串联质谱联用分析，液相色谱仪上样体积为8μL，样品分离梯度为30min，柱流量控制在400nL/min，流动相A相：0.1％甲酸水溶液，B相：含0.1％甲酸的乙腈溶液，柱温为40℃，电喷雾电压2kV；质谱仪参数设置如下：MS:质荷比扫描范围＝100-1500；分辨率＝70000；离子捕获数量＝3e6；最大注入时间＝50ms；扫描电荷＝1-6；高能碰撞(top20)：分辨率＝17500；隔离窗口＝2质荷比；离子捕获数量＝1e5；最大注入时间＝45ms；碰撞能量＝28，动态排除时间＝30s；
(5)分子对接筛选：通过分子对接软件AutodockVina对所得肽序进行模拟对接，筛选出4条与酪氨酸酶螯合最为紧密的肽，这4条肽的序列分别为FSGLD，PFRMY，RGFTGM和APGAPGGGF，并利用Pymol及Discovery Studio软件进行可视化处理。
实施例4
从Protein Data Bank(PDB)数据库获取酪氨酸酶的3D结构(PDB ID：2Y9X)并将其作为受体蛋白，去除受体蛋白的配体及水分子并添加氢原子。采用Chem Draw软件分别绘制五肽FSGLD、五肽PFRMY、六肽RGFTGM和九肽APGAPGGGF的二级结构并利用Minimize Energy模块进行能量最小化处理。AutoDockVina软件中设置网格地图大小为
对接中心坐标值设置为X：-10.09；Y：-28.03；Z：-43.14。以“-Docker Energy”值为筛选指标，该值越小说明酪氨酸酶抑制活性越高，得到4条最具潜在酪氨酸酶抑制活性的肽FSGLD，PFRMY，RGFTGM和APGAPGGGF。4条肽与酪氨酸酶螯合的作用机制通过Discovery Studio软件呈现可视化。
表2四条胶原蛋白源酪氨酸酶抑制肽的分子量及分子对接结果
对液相色谱-串联质谱联用技术鉴定的肽序列进行分子对接筛选得到4条具有最高活性的肽，其分子量大小与对接能如表2所示。对接能越小说明酪氨酸酶抑制活性越高。分子对接结果预测4条肽的酪氨酸酶抑制活性排序如下：PFRMY＞FSGLD＞RGFTGM＞APGAPGGGF，与实际测得的活性结果一致，说明采用分子对接方法筛选高活性酪氨酸酶抑制活性结果可靠。此外，该表亦说明小分子多肽较大分子多肽具有更高的酪氨酸酶抑制活性。
实施例5
实施例制备的胶原蛋白源酪氨酸酶抑制肽在美白面霜中的应用。
含有罗非鱼皮胶原蛋白源酪氨酸酶抑制肽的美白面霜的制备方法，由如下成分制成，按质量份数计：甘油15份，玫瑰精油10份，胶原蛋白源酪氨酸酶抑制肽10份，丁二醇5份，改性硅油5份，沙棘籽油5份，乳化剂5份，烟酰胺3份，维生素C 3份，熊果苷2份，维生素E 2份，透明质酸钠2份，增稠剂2份，吐温80 2份，山梨醇1份，苯氧乙醇0.3份，余量为去离子水。
以上实施例仅用于阐述本发明，而本发明的保护范围并非仅仅局限于以上实施例。在本发明的精神和权利要求的保护范围内，对本发明作出的任何修改和改变，都落入本发明的保护范围。
序列表
<110> 中国水产科学研究院南海水产研究所
<120> 一种胶原蛋白源酪氨酸酶抑制肽及其制备方法与应用
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 5
<212> PRT
<213> 罗非鱼(Oreochromis mossambicus)
<400> 1
Phe Ser Gly Leu Asp
1 5
<210> 2
<211> 5
<212> PRT
<213> 罗非鱼(Oreochromis mossambicus)
<400> 2
Pro Phe Arg Met Tyr
1 5
<210> 3
<211> 6
<212> PRT
<213> 罗非鱼(Oreochromis mossambicus)
<400> 3
Arg Gly Phe Thr Gly Met
1 5
<210> 4
<211> 9
<212> PRT
<213> 罗非鱼(Oreochromis mossambicus)
<400> 4
Ala Pro Gly Ala Pro Gly Gly Gly Phe
1 5
Claims (2)
1.一种胶原蛋白源酪氨酸酶抑制肽，其特征在于，所述胶原蛋白源酪氨酸酶抑制肽的氨基酸序列为RGFTGM或APGAPGGGF。
2.权利要求1所述一种胶原蛋白源酪氨酸酶抑制肽在美白面霜中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111480228.1A CN114163516B (zh) | 2021-12-06 | 2021-12-06 | 一种胶原蛋白源酪氨酸酶抑制肽及其制备方法与应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111480228.1A CN114163516B (zh) | 2021-12-06 | 2021-12-06 | 一种胶原蛋白源酪氨酸酶抑制肽及其制备方法与应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114163516A CN114163516A (zh) | 2022-03-11 |
| CN114163516B true CN114163516B (zh) | 2022-12-30 |
Family
ID=80483744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111480228.1A Active CN114163516B (zh) | 2021-12-06 | 2021-12-06 | 一种胶原蛋白源酪氨酸酶抑制肽及其制备方法与应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114163516B (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114671937A (zh) * | 2022-03-18 | 2022-06-28 | 大连工业大学 | 一种具有酪氨酸酶抑制活性的多肽及其制备方法 |
| CN115634163B (zh) * | 2022-09-09 | 2024-04-26 | 广州睿锶汀化妆品制造有限公司 | 美白护肤精华乳及其制备方法 |
| CN115806588B (zh) * | 2022-11-25 | 2024-05-03 | 中国海洋大学 | 具有酪氨酸酶抑制活性的小分子肽及其应用 |
| CN117964689B (zh) * | 2024-02-01 | 2024-08-02 | 中国水产科学研究院南海水产研究所 | 具有美白活性的多肽、纳米脂质体及其制备方法和应用 |
| CN118146356A (zh) * | 2024-04-02 | 2024-06-07 | 中国水产科学研究院南海水产研究所 | 胶原酶抑制肽及其制备方法与应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101225102A (zh) * | 2008-01-21 | 2008-07-23 | 南昌大学 | 罗非鱼鱼皮多肽螯合锌盐的制备方法 |
| CN101607982A (zh) * | 2008-06-19 | 2009-12-23 | 陈栋梁 | 一种具有美白效果的鱼皮胶原肽及其制备工艺和用途 |
| CN107132360A (zh) * | 2017-05-08 | 2017-09-05 | 南京中医药大学 | 基于串联质谱与分子对接的活性多肽高通量筛选方法 |
-
2021
- 2021-12-06 CN CN202111480228.1A patent/CN114163516B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101225102A (zh) * | 2008-01-21 | 2008-07-23 | 南昌大学 | 罗非鱼鱼皮多肽螯合锌盐的制备方法 |
| CN101607982A (zh) * | 2008-06-19 | 2009-12-23 | 陈栋梁 | 一种具有美白效果的鱼皮胶原肽及其制备工艺和用途 |
| CN107132360A (zh) * | 2017-05-08 | 2017-09-05 | 南京中医药大学 | 基于串联质谱与分子对接的活性多肽高通量筛选方法 |
Non-Patent Citations (3)
| Title |
|---|
| Facile and moderate immobilization of proteases on SPS nanospheres for the active collagen peptides;Qianqian Ye 等;《Food Chemistry》;20200719;第335卷;第6页左栏倒数2段；摘要 * |
| Novel umami peptides from tilapia lower jaw and molecular docking to the taste receptor T1R1/T1R3;Ruan Shiyan 等;《Food Chemistry》;20211115;第362卷;第6页左栏第1段、表1 * |
| 水产蛋白源螯合肽的研究进展;林海燕 等;《食品安全质量检测学报》;20171231;第8卷(第12期);第2.2节 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114163516A (zh) | 2022-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114163516B (zh) | 一种胶原蛋白源酪氨酸酶抑制肽及其制备方法与应用 | |
| CN104450839B (zh) | 具有ace抑制活性的米糠蛋白肽的制备方法 | |
| Liu et al. | Isolation and characterization of a C12‐lipopeptide produced by Bacillus subtilis HSO 121 | |
| CN103242430B (zh) | 血管紧张素转化酶抑制肽及其制备方法和应用 | |
| CN107226836B (zh) | 一种具有改善记忆功效的多肽及其分离制备方法和应用 | |
| CN110317848B (zh) | 一种胶原蛋白肽的制备方法 | |
| CN113005166B (zh) | 具有黄嘌呤氧化酶抑制活性的鳕鱼多肽 | |
| CN106084013B (zh) | 血管紧张素转化酶抑制肽及其制备方法和应用 | |
| CN111100186B (zh) | 一种具有ace抑制活性的河鲀多肽及其制备方法 | |
| CN105820229A (zh) | 一种鸭肫蛋白源抗氧化肽及其应用 | |
| CN114907445B (zh) | 一种高抗氧化活性富硒肽及其应用 | |
| Hu et al. | From fish scale gelatin to tyrosinase inhibitor: A novel peptides screening approach application | |
| Zhang et al. | Changes of antioxidative activities and peptidomic patterns of Auxenochlorella pyrenoidosa protein hydrolysates: Effects of enzymatic hydrolysis and decoloration processes | |
| CN115806588A (zh) | 具有酪氨酸酶抑制活性的小分子肽及其应用 | |
| CN115093456A (zh) | 一种具有抗氧化活性的杏仁多肽及其提取方法、应用 | |
| CN109336953B (zh) | 一种苦荞抗氧化肽及其制备方法和应用 | |
| CN110269129A (zh) | 一种鸭肉源ace抑制肽及其制备方法 | |
| CN106560518A (zh) | 一种绿侧花海葵抗前列腺癌寡肽的制备方法 | |
| CN107759685B (zh) | 一种鲟鱼鱼骨明胶铁螯合肽及其制备方法 | |
| CN107245094B (zh) | 一种抗氧化肽及其分离制备方法和用途 | |
| CN106905416A (zh) | 具有抑制二肽基肽酶‑4的活性肽及其制备方法与应用 | |
| LU502368B1 (en) | Collagen-derived tyrosinase inhibitory peptide and preparation method and application thereof | |
| CN102372765A (zh) | 菲律宾蛤仔酶解多肽及其制备方法 | |
| CN113845565B (zh) | 一种地龙生物活性小肽及其制备方法和应用 | |
| CN116120431A (zh) | 一种抗氧化胶原多肽、制备方法及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |